PLx Pharma Winddown (PLXPQ) 10-K 11 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 08, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001497504
Entity Registrant Name	PLx Pharma Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-36351
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4995704
Entity Address, Address Line One	9 Fishers Lane, Suite E
Entity Address, City or Town	Sparta
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07871
City Area Code	973
Local Phone Number	409-6541
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PLXP
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 335,700,000
Entity Common Stock, Shares Outstanding		27,539,229
Auditor Name	Marcum LLP
Auditor Location	New York, NY
Auditor Firm ID	688
ICFR Auditor Attestation Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 69,392	$ 22,449
Accounts receivable	634	0
Inventory	2,458	143
Prepaid expenses and other current assets	992	394
TOTAL CURRENT ASSETS	73,476	22,986
NON-CURRENT ASSETS
Property and equipment, net	858	1,226
Right of use assets	230	327
Goodwill	2,061	2,061
Security deposit	17	17
TOTAL ASSETS	76,642	26,617
CURRENT LIABILITIES
Accounts payable and accrued liabilities	10,600	863
Accrued bonuses	1,163	1,185
Accrued interest	0	597
Current portion of term loan, net of discount and fees	0	622
Other current liabilities	116	275
TOTAL CURRENT LIABILITIES	11,879	3,542
NON-CURRENT LIABILITIES
Warrant liability	12,818	9,692
Accrued dividends	129	2,796
Other liabilities	136	134
TOTAL LIABILITIES	24,962	16,164
Commitments and contingencies - Note 7
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock; $0.001 par value; 930,000 shares authorized; none issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 27,539,229 and 13,911,633 shares issued and outstanding as of December 31, 2021 and 2020, respectively	28	14
Additional paid-in capital	183,912	91,203
Accumulated deficit	(148,274)	(102,149)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	35,666	(10,932)
TOTAL LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)	76,642	26,617
Series A Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock	13,708	13,662
Series B Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock	$ 2,306	$ 7,723

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	930,000	930,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,539,229	13,911,633
Common stock, shares outstanding (in shares)	27,539,229	13,911,633
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	45,000	45,000
Convertible preferred stock, shares issued (in shares)	12,642	15,000
Convertible preferred stock, shares outstanding (in shares)	12,642	15,000
Convertible preferred stock, liquidation value	$ 12,642,000	$ 12,642,000
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	25,000	25,000
Convertible preferred stock, shares issued (in shares)	2,364	8,000
Convertible preferred stock, shares outstanding (in shares)	2,364	8,000
Convertible preferred stock, liquidation value	$ 2,492,722	$ 2,492,722

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
REVENUES:
TOTAL REVENUES	$ 8,208,000	$ 30,000
Costs of sales	4,805,000	0
GROSS PROFIT	3,403,000	30,000
OPERATING EXPENSES:
Research and development	4,182,000	4,339,000
Selling, marketing and administrative	40,011,000	9,150,000
TOTAL OPERATING EXPENSES	44,193,000	13,489,000
OPERATING LOSS	(40,790,000)	(13,459,000)
OTHER INCOME (EXPENSE):
Interest income (expense), net	1,000	(308,000)
Change in fair value of warrant liability	(5,336,000)	(1,444,000)
TOTAL OTHER INCOME (EXPENSE)	(5,335,000)	(1,752,000)
LOSS BEFORE INCOME TAXES	(46,125,000)	(15,211,000)
Income taxes	0	0
NET LOSS	(46,125,000)	(15,211,000)
Preferred dividends and beneficial conversion feature	(2,525,000)	(1,737,000)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (48,650,000)	$ (16,948,000)
Net loss per common share - basic and diluted (in dollars per share)	$ (2.06)	$ (1.74)
Weighted average shares of common shares - basic and diluted (in shares)	23,650,457	9,714,951
Product [Member]
REVENUES:
TOTAL REVENUES	$ 8,208,000	$ 0
Grant [Member]
REVENUES:
TOTAL REVENUES	$ 0	$ 30,430

Consolidated Statements of Chan

Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series A Preferred Stock [Member]Conversion of Preferred Stock To Common Stock [Member]Preferred Stock [Member]	Series A Preferred Stock [Member]Preferred Stock [Member]	Series A Preferred Stock [Member]Additional Paid-in Capital [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]Conversion of Preferred Stock To Common Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]	Conversion of Preferred Stock To Common Stock [Member]Common Stock [Member]	Conversion of Preferred Stock To Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Preferred Stock To Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019		15,000										9,156,260
Balance at Dec. 31, 2019		$ 13,662										$ 9	$ 74,837	$ (86,938)	$ (12,092)
Stock-based compensation expense													1,289		1,289
Issuance of Series B Preferred Stock, net of issuance costs (in shares)						8,000						4,755,373
Issuance of Series B Preferred Stock, net of issuance costs						$ 7,723						$ 5	16,815		16,820
Preferred stock - declared dividends			$ (1,328)	$ (1,328)			$ (410)	$ (410)
Net income (loss)														(15,211)	(15,211)
Balance (in shares) at Dec. 31, 2020		15,000				8,000						13,911,633
Balance at Dec. 31, 2020		$ 13,662				$ 7,723						$ 14	91,203	(102,149)	(10,932)
Stock-based compensation expense													2,884		2,884
Issuance of Series B Preferred Stock, net of issuance costs (in shares)												9,375,068
Issuance of Series B Preferred Stock, net of issuance costs												$ 10	74,474		74,484
Preferred stock - declared dividends							$ (105)	$ (105)					(217)		(217)
Net income (loss)														(46,125)	(46,125)
Settlement of dividends on Preferred Stock with adjustment of conversion price		$ 2,603				$ 386
Conversion of Preferred Stock (in shares)	(2,358)				(5,636)
Conversion of Preferred Stock	$ (2,557)				$ (5,803)
Conversion of Preferred Stock (in shares)									3,000,000
Conversion of Preferred Stock									$ 3	$ 8,358	$ 8,361
Exercise of Warrants (in shares)												1,252,528
Exercise of Warrants												$ 1	7,315		7,316
Balance (in shares) at Dec. 31, 2021		12,642				2,364						27,539,229
Balance at Dec. 31, 2021		$ 13,708				$ 2,306						$ 28	$ 183,912	$ (148,274)	$ 35,666

Consolidated Statements of Cash

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (46,125)	$ (15,211)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	116	125
Stock-based compensation	2,884	1,289
Amortization of right of use assets	97	291
Amortization of debt discounts and issuance costs	3	92
Change in fair value of warrant liability	5,336	1,444
Loss on disposal of property and equipment	157	218
Changes in operating assets and liabilities
Accounts receivable	(635)	19
Inventory	(2,314)	(144)
Prepaid expenses and other assets	(599)	(74)
Accounts payable and accrued liabilities	9,738	(66)
Accrued bonuses	(22)	18
Accrued interest	(597)	61
Other current and long-term liabilities	(157)	(305)
Net cash used in operating activities	(32,118)	(12,243)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	0	(102)
Proceeds from sale of property and equipment	95	0
Net cash provided by (used in) investing activities	95	(102)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of Series B convertible preferred stock	0	7,723
Net proceeds from issuance of common stock	74,484	16,820
Net proceeds from exercise of warrants	5,107	0
Repayments of long term debt	(625)	(3,750)
Net cash provided by financing activities	78,966	20,793
NET INCREASE IN CASH AND CASH EQUIVALENTS	46,943	8,448
Cash and cash equivalents, beginning of year	22,449	14,001
Cash and cash equivalents, end of year	69,392	22,449
SUPPLEMENTAL INFORMATION
Income taxes	0	0
Interest	6	213
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Cashless exercise of warrants	1,879	0
Preferred stock beneficial conversion feature and dividends	$ 8,035	$ 1,737

Note 1 - Background and Organiz

Note 1 - Background and Organization	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	NOTE 1. Business Operations PLx Pharma Inc. (the “Company”, “we”, “our” or “us”), together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (“APIs”) are absorbed in the gastrointestinal (“GI”) tract via its clinically validated and patent protected PLxGuard™ technology. The Company has two 81 325 Impact of COVID- 19 On March 11, 2020, 19 In response to COVID- 19, not not 19 may not The Company has not December 31, 2021 19.

Note 2 - Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations and potential other funding sources, in addition to cash on-hand, to meet its obligations as they become due. The Company had not September 30, 2021 third 2021. December 31, 2021, 2022. 2021 2025; As of December 31, 2021, December 31, 2021 one

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3. Basis and Accounting and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries, PLx Opco Inc. and PLx Chile SpA. All significant intercompany balances and transactions have been eliminated within the consolidated financial statements. The Company dissolved its subsidiary, PLx Chile SpA, in March 2020. one Use of Estimates The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2021, not Allowance for Uncollectible Accounts Receivable An allowance for uncollectible accounts receivable is estimated based on historical experience, credit quality, age of the accounts receivable balances, and economic conditions that may no December 31, 2021. Inventory Inventory is stated at the lower of cost or net realizable value, using the first first December 31, 2021 2020 December 31, 2021 December 31, 2020 Description (in thousands) Raw Materials $ 132 $ 143 Work-in-Progress 338 - Finished Goods 1,988 - Total Inventory $ 2,458 $ 143 The Company began shipping inventory to its customers in the third 2021. December 31, 2021 2020. Fair Value of Financial Instruments All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. The fair value of the Term Loan (as defined in Note 5 December 31, 2020 8. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. The Company capitalizes additions that have a tangible future economic life. Maintenance and repairs that do not may not Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 December 31, 2021 2020, not Goodwill Goodwill is not October 31, not one The Company performs a one no The Company has not December 31, 2021 2020. Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Through June 30, 2021, second 2020. December 31, 2020. The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 325 third 2021 81 325 December 31, 2021. Nature of Goods and Services The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier. Gross sales to our largest customers for the period ending December 31, 2021 No 10% December 31, 2021. Satisfaction of Performance Obligations The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no December 31, 2021. Variable Consideration Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays. The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs in arriving at coupon reserve requirements and uses forecasted customer and sales organization inputs, and trend analysis for consumer brands in determining the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying consolidated balance sheets in accounts payable and accrued liabilities, was $1.3 million as of December 31, 2021 ( none December 31, 2020). Cost of Sales Cost of sales includes costs related to the manufacture and packaging of the Company’s products charged by our contract manufacturer and packagers. Cost of sales also includes inbound and outbound shipping and warehousing costs, quality assurance and royalties. Selling, Marketing and Administrative Selling, marketing and administrative (“SM&A”) expenses include costs related to functions such as sales, marketing, corporate management, insurance, and legal costs. Broker commissions are incurred and expensed as SM&A costs in the underlying consolidated statements of operations when the underlying sales take place. SM&A expenses also include costs for advertising (excluding the costs of cooperative advertising programs, which are reflected in net sales), contract field force, consumer promotion costs (such as on-shelf advertisements and displays). SM&A costs are expensed as incurred. The Company has not not December 31, 2021 2020. Advertising Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $13.9 million during the year ended December 31, 2021, not December 31, 2020. Research and Development Expenses Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of direct and indirect costs associated with specific projects, manufacturing activities, and include fees paid to various entities that perform research related services for the Company. Stock-Based Compensation The Company recognizes expense in the consolidated statements of operations for the fair value of all stock-based compensation to key employees, nonemployee directors and advisors, generally in the form of stock options. The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options on the grant date. Compensation cost is amortized on a straight-line basis over the vesting period for each respective award. The Company accounts for forfeitures as they occur. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. Tax benefits are initially recognized in the financial statements when it is more likely than not 50% The Company currently has tax returns open for examination by the applicable taxing authority for all years since 2015. Income (Loss) Per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method. Due to net losses, none December 31, 2021 2020. The following table sets forth the potential dilutive securities: December 31, 2021 December 31, 2020 Stock Options 3,498,297 2,979,047 Warrants 6,596,096 7,935,503 Convertible Preferred Stock 6,476,275 9,399,758 Total Potential Dilutive Shares 16,570,668 20,314,308 Recent Accounting Developments In November 2019, 2019 12 1 2 3 not 4 1 2 3 not not 4 5 December 15, 2020, 2019 12 January 1, 2021, not In June 2016, 2016 13 , Financial Instruments-Credit Losses (Topic 326 December 15, 2022, In August 2020, 2020 06 Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (subtopic 815 40 December 15, 2023, The Company does not not

Note 4 - Long-lived Assets

Note 4 - Long-lived Assets	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant, and Equipment and Intangible Assets [Text Block]	NOTE 4. Property and Equipment Property and equipment at December 31, 2021 2020 Asset Descriptions Useful Lives (years) December 31, 2021 December 31, 2020 (in thousands) Computer equipment 4 $ - $ 42 Lab equipment 5 8 17 Office equipment, furniture and fixtures 5 88 106 Leasehold improvements lease term 185 185 Manufacturing equipment 7 1,042 1,324 Subtotal 1,323 1,674 Less: Accumulated depreciation and amortization (465 ) (448 ) Total property and equipment, net $ 858 $ 1,226 Depreciation and amortization expense for the years ended December 31, 2021 2020 December 31, 2021 2020 Goodwill The Company established goodwill in 2017 December 31, 2021 2020 not December 31, 2021 2020. not

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5. Term Loan Facility On August 9, 2017, February 9, 2021), February 9, 2021. may not As of December 31, 2020, December 31, 2021 2020

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6. EQUITY Common Stock On March 5, 2021, 30 March 16, 2021 In November 2020, November 18, 2020. five ATM Offering On August 6, 2021, may 3, one December 31, 2021. December 31, 2021, “2019 March 2019 2019 March 2, 2021. 2020 2019 December 31, 2020, 2019 Convertible Preferred Stock Series A Preferred Stock In December 2018, February 19, 2019. February 20, 2019, $15.0 The Series A Preferred Stock was issued at $1,000 per share and was initially convertible into shares of common stock at a conversion price of $2.60 per share, subject to certain adjustments. Holders of the Series A Preferred Stock were entitled to an initial dividend rate of 8.0% per annum, which ended on February 26, 2021, 81 325 In June 2021, As of December 31, 2021, December 31, 2021. The Company recognized $2.4 million (or $0.10 per share) of total dividends on the Series A Preferred Stock (including the contingent beneficial conversion feature) during the year ended December 31, 2021. December 31, 2020. Series B Preferred Stock In March 2020, May 15, 2020. May 15, 2020, $8.0 February 26, 2021, 81 325 In June 2021, not As of December 31, 2021, December 31, 2021. The Company recognized $0.1 million (or $0.004 per share) of total dividends on the Series B Preferred Stock during the year ended December 31, 2021. December 31, 2020. Warrants In June 2017, six one “June 2017 8 In connection with the entry into the Term Loan Facility, the Company issued to SVB and one In November 2020, five “November 2020 During the year ended December 31, 2021, June 2017 November 2020 The following is a summary of warrant activities for the year ended December 31, 2021: Description Outstanding 12/31/2020 Exercised Outstanding 12/31/2021 Exercise Price Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) June 2017 Warrants 2,646,091 (188,590 ) 2,457,501 $ 7.50 5.45 $ 1,253 November 2020 Warrants 5,230,910 (1,121,566 ) 4,109,344 $ 4.31 5.60 $ 47 SVB Warrants 58,502 (29,251 ) 29,251 $ 6.41 3.88 $ 15,205 Total Warrants 7,935,503 (1,339,407 ) 6,596,096 $ 4.47 5.51 $ 16,505 Stock Options Following is a summary of option activities for the years ended December 31, 2021 2020: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding, January 1, 2021 2,979,047 $ 9.35 7.84 $ 2,074 Granted 528,000 $ 15.28 Cancelled (8,750 ) $ 81.28 Outstanding, December 31, 2021 3,498,297 $ 10.07 7.27 $ 7,456 Exercisable, December 31, 2021 1,805,847 $ 12.21 5.87 $ 3,097 On September 13, 2018, 2018 “2018 2018 may November 10, 2020, 2020 2018 2018 November 9, 2021, 2021 2018 2018 August 3, 2021, 2018 2018 Prior to the approval of the 2018 two 2013 2018 no no two The Company granted options to purchase 528,000 shares of common stock during the year ended December 31, 2021 1 2 3 4 zero The Company granted options to purchase 1,511,000 shares of common stock during the year ended December 31, 2020 1 2 3 4 zero As of December 31, 2021, During the years ended December 31, 2021 2020 December 31, 2021, December 31, 2020,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 7. Lease Agreements The Company presently leases office space under operating lease agreements, expiring in September 2023 June 2024. December 31, 2021 2020, In the second 2021, September 2023. Operating lease ROU assets are included in right of use assets in the Company's consolidated balance sheets. Operating lease liabilities are included in other current and non-current liabilities in the Company’s consolidated balance sheets. All the Company’s existing leases as of December 31, 2021 none July 2021. Lease costs, net of sublease income, for the year ended December 31, 2021 (in thousands) Operating lease cost $ 258 Sublease income (145 ) Total lease costs $ 113 A maturity analysis of the Company’s operating leases follows: Future undiscounted cash flows: (in thousands) 2022 $ 132 2023 114 2024 30 2025 - Total 276 Discount factor (25 ) Total lease liability 251 Current lease liability (115 ) Non-current lease liability $ 136 Patent License Agreement with the Board of Regents of the University of Texas ( NSAIDs ) On January 8, 2003, Under terms of the agreement, the Company is responsible for conducting clinical trials involving investigational use of a licensed product for the determination of metabolic and pharmacologic actions in humans, the side effects associated with increasing doses, examination of suspected indications, determination of the potential short-term side effects in humans and for establishing the safety, efficacy, labeled indications and risk-benefit profile in humans. The patent license agreement also requires the Company to provide reimbursement for all expenses incurred by The University of Texas Health Science Center at Houston for filing, prosecuting, enforcing, and maintaining patent rights and requires an annual nonrefundable license management fee. In addition, the Company is obligated to pay certain milestone payments in future years relating to royalties resulting from the approval to sell licensed products and the resulting sales of such licensed products. The Company recognized total expenses of $0.2 million and $0.3 million related to the UT in the years ended December 31, 2021 2020, Purchase Commitments As of December 31, 2021, 2022. The Company has supply agreements with its contract manufacturer and packager for VAZALORE which contain minimum annual purchase commitments starting in 2021 2025.

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 8. Fair value is defined as the price that would be received in the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has categorized all investments recorded at fair value based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: ● Level 1: ● Level 2: 1, ● Level 3: The Company’s financial instruments (cash and cash equivalents, receivables, and accounts payable) are carried in the consolidated balance sheet at cost, which reasonably approximates fair value based on their short-term nature. The Company’s warrant liability is recorded at fair value, with changes in fair value being reflected in the statements of operations for the period of change. Financial assets and liabilities measured at fair value on a recurring basis The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The June 2017 3 one December 31, 2021 1 2 3 4 December 31, 2020 1 2 3 4 The Series A Preferred Stock and the Series B Preferred Stock both contain a contingent put option and, accordingly, the Company considered the put options to be liabilities and accounted for them at fair value using Level 3 de minimis December 31, 2021, 3 The following table sets forth a summary of changes in the fair value of Level 3 December 31, 2021 2020: Description Balance at December 31, 2019 Established in 2020 Change in Fair Value Balance at December 31, 2020 (in thousands) Warrant liability $ 8,248 $ - $ 1,444 $ 9,692 Description Balance at December 31, 2020 Exercised in 2021 Change in Fair Value Balance at December 31, 2021 (in thousands) Warrant liability $ 9,692 $ (2,210 ) $ 5,336 $ 12,818 The following table identifies the carrying amounts of such liabilities at December 31, 2021 2020: Level 1 Level 2 Level 3 Total (in thousands) Warrant liability $ - $ - $ 9,692 $ 9,692 Balance at December 31, 2020 $ - $ - $ 9,692 $ 9,692 Level 1 Level 2 Level 3 Total (in thousands) Warrant liability $ - $ - $ 12,818 $ 12,818 Balance at December 31, 2021 $ - $ - $ 12,818 $ 12,818 Financial assets and liabilities carried at fair value on a non-recurring basis The Company does not Non-financial assets and liabilities carried at fair value on a recurring basis The Company does not Non-financial assets and liabilities carried at fair value on a non-recurring basis The Company measures its long-lived assets, including property and equipment and goodwill, at fair value on a non-recurring basis when they are deemed to be impaired. No such impairment was recognized in the years ended December 31, 2021 2020.

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9. Income tax (expense) benefit for the years ended December 31, 2021 2020 Year Ended December 31, 2021 Year Ended December 31, 2020 (in thousands) Current: Federal $ - $ - State - - Foreign - - Deferred: Federal 7,867 3,211 State (1,454 ) 1,101 Foreign - - Change in valuation allowance (6,413 ) (4,312 ) Total Benefit for Income Taxes $ - $ - Significant components of the Company's deferred tax assets and liabilities consisted of the following at December 31, 2021 2020: December 31, 2021 December 31, 2020 (in thousands) Deferred tax assets: Stock-based compensation $ 4,710 $ 4,898 Tax credit carryforwards 2,415 2,203 Net operating loss carryforwards 29,497 23,118 Intangible assets 437 599 Other 583 443 Total deferred tax assets 37,642 31,261 Deferred tax liabilities: Property and equipment and right of use assets 183 215 Total deferred tax liabilities 182,614 215 Net deferred tax assets 37,459 31,046 Less valuation allowance (37,459 ) (31,046 ) Total deferred tax assets (liabilities) $ - $ - The following table reconciles the U.S. federal statutory income tax rate in effect for 2021 2020 Year Ended December 31, 2021 Year Ended December 31, 2020 U.S. federal statutory income tax expense (benefit) 21.0 % 21.0 % State and local income tax, net of benefits 1.2 % 7.2 % Change in fair value of derivatives (2.7 %) (2.7 %) Change in tax rates (6.1 %) 1.0 True-up and other 0.5 % 1.8 % Change in valuation allowance for deferred income tax assets (13.9 %) (28.3 %) Effective income tax rate 0.0 % 0.0 % The Company had net operating loss carry-forwards of $134.9 million as of December 31, 2021, may 2035. may not Utilization of net operating loss and tax credit carryforwards may may three 50 382 December 31, 2017. As of December 31, 2021, 2016 2020 740, not not 382 December 31, 2021 2020. December 31, 2021, As of December 31, 2021 2020, no No December 31, 2021 2020. not twelve

Note 10 - Subsequent Events

Note 10 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10. The Company’s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration and none

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and Accounting and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries, PLx Opco Inc. and PLx Chile SpA. All significant intercompany balances and transactions have been eliminated within the consolidated financial statements. The Company dissolved its subsidiary, PLx Chile SpA, in March 2020. one
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2021, not
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Uncollectible Accounts Receivable An allowance for uncollectible accounts receivable is estimated based on historical experience, credit quality, age of the accounts receivable balances, and economic conditions that may no December 31, 2021.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value, using the first first December 31, 2021 2020 December 31, 2021 December 31, 2020 Description (in thousands) Raw Materials $ 132 $ 143 Work-in-Progress 338 - Finished Goods 1,988 - Total Inventory $ 2,458 $ 143 The Company began shipping inventory to its customers in the third 2021. December 31, 2021 2020.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. The fair value of the Term Loan (as defined in Note 5 December 31, 2020 8.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. The Company capitalizes additions that have a tangible future economic life. Maintenance and repairs that do not may not
Lessee, Leases [Policy Text Block]	Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 December 31, 2021 2020, not
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill Goodwill is not October 31, not one The Company performs a one no The Company has not December 31, 2021 2020.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Through June 30, 2021, second 2020. December 31, 2020. The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 325 third 2021 81 325 December 31, 2021. Nature of Goods and Services The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier. Gross sales to our largest customers for the period ending December 31, 2021 No 10% December 31, 2021. Satisfaction of Performance Obligations The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no December 31, 2021. Variable Consideration Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays. The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs in arriving at coupon reserve requirements and uses forecasted customer and sales organization inputs, and trend analysis for consumer brands in determining the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying consolidated balance sheets in accounts payable and accrued liabilities, was $1.3 million as of December 31, 2021 ( none December 31, 2020). Cost of Sales Cost of sales includes costs related to the manufacture and packaging of the Company’s products charged by our contract manufacturer and packagers. Cost of sales also includes inbound and outbound shipping and warehousing costs, quality assurance and royalties. Selling, Marketing and Administrative Selling, marketing and administrative (“SM&A”) expenses include costs related to functions such as sales, marketing, corporate management, insurance, and legal costs. Broker commissions are incurred and expensed as SM&A costs in the underlying consolidated statements of operations when the underlying sales take place. SM&A expenses also include costs for advertising (excluding the costs of cooperative advertising programs, which are reflected in net sales), contract field force, consumer promotion costs (such as on-shelf advertisements and displays). SM&A costs are expensed as incurred. The Company has not not December 31, 2021 2020.
Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $13.9 million during the year ended December 31, 2021, not December 31, 2020.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of direct and indirect costs associated with specific projects, manufacturing activities, and include fees paid to various entities that perform research related services for the Company.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company recognizes expense in the consolidated statements of operations for the fair value of all stock-based compensation to key employees, nonemployee directors and advisors, generally in the form of stock options. The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options on the grant date. Compensation cost is amortized on a straight-line basis over the vesting period for each respective award. The Company accounts for forfeitures as they occur.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. Tax benefits are initially recognized in the financial statements when it is more likely than not 50% The Company currently has tax returns open for examination by the applicable taxing authority for all years since 2015.
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method. Due to net losses, none December 31, 2021 2020. The following table sets forth the potential dilutive securities: December 31, 2021 December 31, 2020 Stock Options 3,498,297 2,979,047 Warrants 6,596,096 7,935,503 Convertible Preferred Stock 6,476,275 9,399,758 Total Potential Dilutive Shares 16,570,668 20,314,308
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In November 2019, 2019 12 1 2 3 not 4 1 2 3 not not 4 5 December 15, 2020, 2019 12 January 1, 2021, not In June 2016, 2016 13 , Financial Instruments-Credit Losses (Topic 326 December 15, 2022, In August 2020, 2020 06 Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (subtopic 815 40 December 15, 2023, The Company does not not

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2021 December 31, 2020 Description (in thousands) Raw Materials $ 132 $ 143 Work-in-Progress 338 - Finished Goods 1,988 - Total Inventory $ 2,458 $ 143
Incremental Weighted Average Shares Attributable to Dilutive Effect [Table Text Block]	December 31, 2021 December 31, 2020 Stock Options 3,498,297 2,979,047 Warrants 6,596,096 7,935,503 Convertible Preferred Stock 6,476,275 9,399,758 Total Potential Dilutive Shares 16,570,668 20,314,308

Note 4 - Long-lived Assets (Tab

Note 4 - Long-lived Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	Asset Descriptions Useful Lives (years) December 31, 2021 December 31, 2020 (in thousands) Computer equipment 4 $ - $ 42 Lab equipment 5 8 17 Office equipment, furniture and fixtures 5 88 106 Leasehold improvements lease term 185 185 Manufacturing equipment 7 1,042 1,324 Subtotal 1,323 1,674 Less: Accumulated depreciation and amortization (465 ) (448 ) Total property and equipment, net $ 858 $ 1,226

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Description Outstanding 12/31/2020 Exercised Outstanding 12/31/2021 Exercise Price Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) June 2017 Warrants 2,646,091 (188,590 ) 2,457,501 $ 7.50 5.45 $ 1,253 November 2020 Warrants 5,230,910 (1,121,566 ) 4,109,344 $ 4.31 5.60 $ 47 SVB Warrants 58,502 (29,251 ) 29,251 $ 6.41 3.88 $ 15,205 Total Warrants 7,935,503 (1,339,407 ) 6,596,096 $ 4.47 5.51 $ 16,505
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding, January 1, 2021 2,979,047 $ 9.35 7.84 $ 2,074 Granted 528,000 $ 15.28 Cancelled (8,750 ) $ 81.28 Outstanding, December 31, 2021 3,498,297 $ 10.07 7.27 $ 7,456 Exercisable, December 31, 2021 1,805,847 $ 12.21 5.87 $ 3,097

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	(in thousands) Operating lease cost $ 258 Sublease income (145 ) Total lease costs $ 113
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(in thousands) 2022 $ 132 2023 114 2024 30 2025 - Total 276 Discount factor (25 ) Total lease liability 251 Current lease liability (115 ) Non-current lease liability $ 136

Note 8 - Fair Value Measureme_2

Note 8 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Description Balance at December 31, 2019 Established in 2020 Change in Fair Value Balance at December 31, 2020 (in thousands) Warrant liability $ 8,248 $ - $ 1,444 $ 9,692 Description Balance at December 31, 2020 Exercised in 2021 Change in Fair Value Balance at December 31, 2021 (in thousands) Warrant liability $ 9,692 $ (2,210 ) $ 5,336 $ 12,818
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total (in thousands) Warrant liability $ - $ - $ 9,692 $ 9,692 Balance at December 31, 2020 $ - $ - $ 9,692 $ 9,692 Level 1 Level 2 Level 3 Total (in thousands) Warrant liability $ - $ - $ 12,818 $ 12,818 Balance at December 31, 2021 $ - $ - $ 12,818 $ 12,818

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2021 Year Ended December 31, 2020 (in thousands) Current: Federal $ - $ - State - - Foreign - - Deferred: Federal 7,867 3,211 State (1,454 ) 1,101 Foreign - - Change in valuation allowance (6,413 ) (4,312 ) Total Benefit for Income Taxes $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2021 December 31, 2020 (in thousands) Deferred tax assets: Stock-based compensation $ 4,710 $ 4,898 Tax credit carryforwards 2,415 2,203 Net operating loss carryforwards 29,497 23,118 Intangible assets 437 599 Other 583 443 Total deferred tax assets 37,642 31,261 Deferred tax liabilities: Property and equipment and right of use assets 183 215 Total deferred tax liabilities 182,614 215 Net deferred tax assets 37,459 31,046 Less valuation allowance (37,459 ) (31,046 ) Total deferred tax assets (liabilities) $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 Year Ended December 31, 2020 U.S. federal statutory income tax expense (benefit) 21.0 % 21.0 % State and local income tax, net of benefits 1.2 % 7.2 % Change in fair value of derivatives (2.7 %) (2.7 %) Change in tax rates (6.1 %) 1.0 True-up and other 0.5 % 1.8 % Change in valuation allowance for deferred income tax assets (13.9 %) (28.3 %) Effective income tax rate 0.0 % 0.0 %

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($) $ in Millions	Dec. 31, 2021	Sep. 30, 2021
Working Capital		$ 61.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance		69.4
Media and Advertising Commitments [Member]
Other Commitment, Total	$ 6.2	$ 6.2

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2021USD ($)	Aug. 09, 2017USD ($)
Cash, Uninsured Amount	$ 69,400,000	$ 69,400,000
Inventory Valuation Reserves, Ending Balance	0	0	$ 0
Finance Lease, Liability, Total	0	$ 0	0
Number of Reporting Units		1
Goodwill, Impairment Loss	0		0
Revenue from Contract with Customer, Including Assessed Tax		$ 8,208,000	30,000
Reserves for Sales Returns and Consumer and Trade Promotion Obligations	1,300,000	1,300,000		$ 0
Contract with Customer, Asset, before Allowance for Credit Loss, Total	$ 0	0	0
Advertising Expense		13,900,000	0
Dilutive Securities, Effect on Basic Earnings Per Share, Total		$ 0	0
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer A [Member]
Concentration Risk, Percentage		30.20%
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer B [Member]
Concentration Risk, Percentage		19.60%
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Customer C [Member]
Concentration Risk, Percentage		12.30%
Grant [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 0	30,430
VAZALORE [Member]
Revenue from Contract with Customer, Including Assessed Tax		8,200,000
VAZALORE 81 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 5,600,000
VAZALORE 81 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage		68.00%
VAZALORE 325 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 2,600,000
VAZALORE 325 mg Dose [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage		32.00%
Term Loan Facility [Member] | Silicon Valley Bank (SVB) [Member]
Debt Instrument, Face Amount			$ 600,000		$ 7,500,000

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Raw Materials	$ 132	$ 143
Work-in-Progress	338	0
Finished Goods	1,988	0
Total Inventory	$ 2,458	$ 143

Note 3 - Summary of Significa_5

Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Options (in shares)	3,498,297	2,979,047
Warrants (in shares)	6,596,096	7,935,503
Convertible Preferred Stock (in shares)	6,476,275	9,399,758
Total Potential Dilutive Shares (in shares)	16,570,668	20,314,308

Note 4 - Long-lived Assets (Det

Note 4 - Long-lived Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended		21828 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020
Depreciation, Total	$ 100	$ 100
Goodwill, Ending Balance	2,061	2,061	$ 2,061
Goodwill, Impaired, Accumulated Impairment Loss	0	$ 0	0
Equipment [Member]
Gain (Loss) on Disposition of Assets, Total	$ 200		$ 200

Note 4 - Long-lived Assets - Pr

Note 4 - Long-lived Assets - Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total property and equipment, gross	$ 1,323	$ 1,674
Less: Accumulated depreciation and amortization	(465)	(448)
Total property and equipment, net	$ 858	1,226
Computer Equipment [Member]
Total property and equipment, useful lives (Year)	4 years
Total property and equipment, gross	$ 0	42
Lab Equipment [Member]
Total property and equipment, useful lives (Year)	5 years
Total property and equipment, gross	$ 8	17
Office Equipment, Furniture and Fixtures [Member]
Total property and equipment, useful lives (Year)	5 years
Total property and equipment, gross	$ 88	106
Leasehold Improvements [Member]
Total property and equipment, gross	$ 185	185
Machinery and Equipment [Member]
Total property and equipment, useful lives (Year)	7 years
Total property and equipment, gross	$ 1,042	$ 1,324

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual) - Term Loan Facility [Member] - Silicon Valley Bank (SVB) [Member] - USD ($) $ in Thousands	Aug. 09, 2017	Dec. 31, 2021	Dec. 31, 2020	Feb. 09, 2021
Debt Instrument, Face Amount	$ 7,500		$ 600
Debt Instrument, Final Payment Fee, Percentage				8.00%
Interest Expense, Debt, Total		$ 10	$ 400
Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	4.00%
Debt Instrument, Interest Rate, Effective Percentage				7.25%

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity (Details Textual) - USD ($)	Nov. 09, 2021	Aug. 06, 2021	Mar. 16, 2021	Mar. 05, 2021	May 15, 2020	Feb. 20, 2019	Sep. 13, 2018	Aug. 09, 2017	Jun. 30, 2021	Nov. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 4.47
Proceeds from Issuance of Common Stock, Net Issuance Costs											$ 74,484,000	$ 16,820,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											0	0
Class of Warrant or Right, Exercised During Period (in shares)											1,339,407
Proceeds from Warrant Exercises											$ 5,107,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)											528,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount											$ 7,500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)											2 years 8 months 12 days
Share-based Payment Arrangement, Expense											$ 2,900,000	1,300,000
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense											2,800,000	$ 1,300,000
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense											$ 100,000
The 2018 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	4,000,000						1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)							7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)							4,429,650
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)											528,000	1,511,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value											$ 5,600,000	$ 4,300,000
The 2018 Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%
The 2018 Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)												6 years	6 years
The 2018 Incentive Plan [Member] | Minimum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate											0.60%	0.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate											81.00%	81.00%
The 2018 Incentive Plan [Member] | Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate											1.10%	0.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate											87.00%	84.00%
June 2017 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								58,502						2,646,091
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 6.41			$ 7.50			$ 7.50
Warrants and Rights Outstanding, Term (Year)														10 years
Class of Warrant or Right, Term (Year)								10 years
Class of Warrant or Right, Exercised During Period (in shares)											188,590
November 2020 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 4.31
Class of Warrant or Right, Exercised During Period (in shares)											1,121,566
SVB Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 6.41
Class of Warrant or Right, Exercised During Period (in shares)											29,251
June 2017 Warrants and November 2020 Warrants [Member]
Class of Warrant or Right, Exercised During Period, Cashless Basis (in shares)											181,477
Class of Warrant or Right, Exercised During Period, Cash Basis (in shares)											1,157,930
Proceeds from Warrant Exercises											$ 5,100,000
Adjustments to Additional Paid in Capital, Warrants Exercised											$ 7,300,000
Stock Issued During Period, Shares, Exercise of Warrants (in shares)											1,252,528
Conversion Of Series A Preferred Stock To Common Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)									$ 2.22		$ 2.22
Conversion of Stock, Shares Converted (in shares)									2,358
Dividends Payable									$ 2,600,000
Adjustments to Additional Paid in Capital, Preferred Stock Beneficial Conversion Feature, Deemed Dividend									$ 2,200,000
Conversion of Stock, Shares Issued (in shares)									1,064,516
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											12,642
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						15,000
Shares Issued, Price Per Share (in dollars per share)						$ 1,000
Proceeds from Issuance of Private Placement						$ 15,000,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)						$ 2.60
Preferred Stock, Dividend Rate, Percentage						8.00%
Preferred Stock, Liquidation Preference, Value						$ 1,000
Temporary Equity, Par Value											$ 13,700,000
Dividends, Preferred Stock, Total											$ 2,400,000
Preferred Stock, Dividends Per Share, Declared (in dollars per share)											$ 0.10	$ 0.14
Payments of Stock Issuance Costs												$ 1,300,000
Series B Preferred Stock [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 3.10				$ 3.10		$ 3.10
Preferred Stock, Dividend Rate, Percentage					8.00%
Preferred Stock, Liquidation Preference, Value					$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											2,000
Temporary Equity, Par Value											$ 2,300,000
Preferred Stock, Dividends Per Share, Declared (in dollars per share)											$ 0.004	$ 0.04
Payments of Stock Issuance Costs											$ 100,000	$ 400,000
Conversion Of Series B Preferred Stock To Common Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)									$ 2.91		$ 2.91
Conversion of Stock, Shares Converted (in shares)									5,636
Conversion of Stock, Shares Issued (in shares)									1,935,484
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											364
Dividends, Preferred Stock, Total									$ 400,000
JMP Securities, Inc [Member]
Stock Issued During Period, Shares, New Issues (in shares)											450,368	0
Proceeds from Issuance of Common Stock											$ 8,000,000
Distribution Agreement, Aggregate Sales Price		$ 75,000,000									$ 12,500,000
Public Offering Price Allowed under Shelf Registration, Total		$ 250,000,000
Sale of Stock Agent Fees Percent											3.00%
Proceeds from Issuance of Common Stock, Net Issuance Costs											$ 7,600,000
Distribution Agreement, Amount Available for Sale											$ 67,000,000	$ 10,200,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)											9,375,068	4,755,373
Stock Issued During Period, Shares, Exercise of Warrants (in shares)											1,252,528
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				7,875,000
Shares Issued, Price Per Share (in dollars per share)				$ 8
Proceeds from Issuance of Common Stock				$ 63,000,000
Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs				59,000,000
Underwriting Discounts and Commissions and Other Offering Expenses				$ 4,000,000
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,049,700
Proceeds from Issuance of Common Stock			$ 8,400,000
Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs			$ 7,900,000
Sale of Stock, Option to Purchase Shares (in shares)				1,181,250
Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Total										$ 18,000,000
Proceeds from Issuance or Sale of Equity, Net of Allocated Issuance Costs										16,800,000
Placement Agent and Other Offering Expenses										$ 1,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										5,230,910
Stock Issued Per Unit Price (in dollars per share)										$ 3.787
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 4.31
Warrants and Rights Outstanding, Term (Year)										5 years
Private Placement [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					8,000
Proceeds from Issuance of Private Placement					$ 8,000,000
Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)										4,755,373
November 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										5,230,910
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 4.31
Warrants and Rights Outstanding, Term (Year)										5 years

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Summary of Warrant Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Aug. 09, 2017	Jun. 30, 2017
Warrants outstanding (in shares)	6,596,096	7,935,503
Warrants exercised (in shares)	(1,339,407)
Warrants exercise price (in dollars per share)	$ 4.47
Remaining Contractual Term (Year)	5 years 6 months 3 days
Aggregate Intrinsic Value	$ 16,505
June 2017 Warrants [Member]
Warrants outstanding (in shares)	2,457,501	2,646,091
Warrants exercised (in shares)	(188,590)
Warrants exercise price (in dollars per share)	$ 7.50		$ 6.41	$ 7.50
Remaining Contractual Term (Year)	5 years 5 months 12 days
Aggregate Intrinsic Value	$ 1,253
November 2020 Warrants [Member]
Warrants outstanding (in shares)	4,109,344	5,230,910
Warrants exercised (in shares)	(1,121,566)
Warrants exercise price (in dollars per share)	$ 4.31
Remaining Contractual Term (Year)	5 years 7 months 6 days
Aggregate Intrinsic Value	$ 47
SVB Warrants [Member]
Warrants outstanding (in shares)	29,251	58,502
Warrants exercised (in shares)	(29,251)
Warrants exercise price (in dollars per share)	$ 6.41
Remaining Contractual Term (Year)	3 years 10 months 17 days
Aggregate Intrinsic Value	$ 15,205

Note 6 - Stockholders' Equity_3

Note 6 - Stockholders' Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding, number of units, balance (in shares)	2,979,047
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 9.35
Outstanding, weighted average remaining contractual term (Year)	7 years 3 months 7 days	7 years 10 months 2 days
Granted, number of units (in shares)	528,000
Granted, weighted average exercise price (in dollars per share)	$ 15.28
Cancelled, number of units (in shares)	(8,750)
Cancelled, weighted average exercise price (in dollars per share)	$ 81.28
Outstanding, number of units, balance (in shares)	3,498,297	2,979,047
Outstanding, weighted average exercise price, balance (in dollars per share)	$ 10.07	$ 9.35
Outstanding, aggregate intrinsic value	$ 7,456
Exercisable, number of units (in shares)	1,805,847
Exercisable, weighted average exercise price (in dollars per share)	$ 12.21
Exercisable, weighted average remaining contractual term (Year)	5 years 10 months 13 days
Exercisable, aggregate intrinsic value	$ 3,097

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Operating Lease, Expense		$ 100	$ 400
Increase (Decrease) in Operating Lease Right of Use Asset		$ (97)	(291)
Operating Lease, Weighted Average Remaining Lease Term (Year)		2 years 1 month 6 days
Research and Development Expense, Total		$ 4,182	4,339
Media and Advertising Commitments [Member]
Other Commitment, Total		6,200		$ 6,200
Patent License Agreement with the Board of Regents of the University of Texas (NSAIDs) [Member]
Research and Development Expense, Total		$ 200	$ 300
Minimum [Member]
Lessee, Operating Lease, Discount Rate		7.25%
Maximum [Member]
Lessee, Operating Lease, Discount Rate		9.50%
Office Lease [Member]
Increase (Decrease) in Operating Lease Right of Use Asset	$ 100
Lessee, Operating Lease, Discount Rate	7.25%

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Lease Costs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Operating lease cost	$ 258
Sublease income	(145)
Total lease costs	$ 113

Note 7 - Commitments and Cont_5

Note 7 - Commitments and Contingencies - Maturity of Operating Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
2022	$ 132
2023	114
2024	30
2025	0
Total	276
Discount factor	(25)
Total lease liability	251
Other Current Liabilities [Member]
Current lease liability	(115)
Other Noncurrent Liabilities [Member]
Non-current lease liability	$ 136

Note 8 - Fair Value Measureme_3

Note 8 - Fair Value Measurements (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Asset Impairment Charges, Total	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	8.01	5.52
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.30	0.57
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	6.5
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	84	82

Note 8 - Fair Value Measureme_4

Note 8 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) - Derivative Warrant Liability [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 9,692	$ 8,248
Established	(2,210)	0
Change in fair value	5,336	1,444
Balance	$ 12,818	$ 9,692

Note 8 - Fair Value Measureme_5

Note 8 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 12,818	$ 9,692
Derivative Warrant Liability [Member]
Liability	12,818	9,692
Fair Value, Inputs, Level 1 [Member]
Balance	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative Warrant Liability [Member]
Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Balance	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative Warrant Liability [Member]
Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Balance	12,818	9,692
Fair Value, Inputs, Level 3 [Member] | Derivative Warrant Liability [Member]
Liability	$ 12,818	$ 9,692

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards, Total	$ 134,900
Operating Loss Carryforwards, Beginning Expiration Year	2035
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 6,413	$ 4,312

Note 9 - Income Taxes - Income

Note 9 - Income Taxes - Income Tax (Expense) Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Federal, current	$ 0	$ 0
State, current	0	0
Foreign, current	0	0
Federal, deferred	7,867	3,211
State, deferred	(1,454)	1,101
Foreign, deferred	0	0
Change in valuation allowance	(6,413)	(4,312)
Total Benefit for Income Taxes	$ 0	$ 0

Note 9 - Income Taxes - Signifi

Note 9 - Income Taxes - Significant Components of the Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation	$ 4,710	$ 4,898
Tax credit carryforwards	2,415	2,203
Net operating loss carryforwards	29,497	23,118
Intangible assets	437	599
Other	583	443
Total deferred tax assets	37,642	31,261
Property and equipment and right of use assets	183	215
Total deferred tax liabilities	182,614	215
Net deferred tax assets	37,459	31,046
Less valuation allowance	(37,459)	(31,046)
Total deferred tax assets (liabilities)	$ 0	$ 0

Note 9 - Income Taxes - Incom_2

Note 9 - Income Taxes - Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
U.S. federal statutory income tax expense (benefit)	21.00%	21.00%
State and local income tax, net of benefits	1.20%	7.20%
Change in fair value of derivatives	(2.70%)	(2.70%)
Change in tax rates	(6.10%)	1.00%
True-up and other	0.50%	1.80%
Change in valuation allowance for deferred income tax assets	(13.90%)	(28.30%)
Effective income tax rate	0.00%	0.00%